Catatonia and the Neuroleptic Malignant Syndrome – a Single Entity?

1992 ◽  
Vol 161 (4) ◽  
pp. 558-560 ◽  
Author(s):  
D. A. C. White
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Muscular Rigidity ◽  
Single Entity ◽  
Prior Administration

Separate episodes of both catatonia and the so-called ‘neuroleptic malignant syndrome’ (NMS) occurred within the same patient. The only evidence for NMS in this case was prior administration of a neuroleptic and the presence of generalised muscular rigidity. It is suggested that it is misleading to view these conditions as separate diagnostic entities and that NMS is probably more correctly incorporated into the catatonic disorders.

Neuroleptic Malignant Syndrome in Striatonigral Degeneration

1988 ◽  
Vol 153 (2) ◽  
pp. 254-255 ◽  
Author(s):  
W. R. G. Gibb
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Heat Production ◽  
Striatal Dopamine ◽  
Striatonigral Degeneration ◽  
Muscular Rigidity

A case of probable neuroleptic malignant syndrome (NMS) complicating l-dopa withdrawal in striatonigral degeneration is described. This case suggests that the hyperthermia of NMS is due to peripheral heat production associated with severe muscular rigidity secondary to withdrawal of striatal dopamine drive, rather than being centrally mediated by the hypothalamus, which is not involved in striatonigral degeneration.

The Aftercare of the Patient with the Neuroleptic Malignant Syndrome

1985 ◽  
Vol 146 (3) ◽  
pp. 317-318 ◽  
Author(s):  
Dov Aizenberg ◽  
Arieh Shalev ◽  
Hanan Munitz
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Autonomic Dysfunction ◽  
Neuroleptic Drugs ◽  
Anti Psychotic ◽  
Idiosyncratic Reaction ◽  
Muscular Rigidity ◽  
Level Of Consciousness

SummaryThe neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to neuroleptic drugs, made up of hyperthermia, muscular rigidity, disturbance of level of consciousness and autonomic dysfunction. It is potentially lethal and should be kept in mind whilst using anti-psychotic drugs; as most patients treated by them require further anti-psychotic treatment, the clinician faces the problem of treating those patients after a NMS episode, yet reports in the literature have generally neglected the problem of late management. A patient suffering from a psychosis and NMS is presented, and a rationale for management offered.

The Effect of Haematoporphyrin Derivative on the Uptake of 67Ga, 59Fe and 65Zn in Tumours

1978 ◽  
Vol 17 (06) ◽  
pp. 262-265
Author(s):  
A. Phillips Carol ◽  
D.M. Taylor
Keyword(s):  
Fold Increase ◽  
Haematoporphyrin Derivative ◽  
Tumour Bearing ◽  
Rats And Mice ◽  
Prior Administration

The effect of prior administration of haematoporphyrin derivative on the uptake in tumours of 67Ga, 59Fe and 65Zn has been studied in tumour-bearing rats and mice. An approximately two-fold increase in the uptake of 67Ga was observed in the August 15 rat tumour when the nuclide was administered 17 to 24 hr after haematoporphyrin. No increase in the uptake of 67Ga occurred in three mouse tumours. Haematoporphyrin administration did not affect the uptake of 65Zn and 59Fe in any of the tumour systems. It is concluded that the presence of haematoporphyrin does not markedly increase the ability of tumours to accummulate metallic radionuclides.

NEUROLEPTIC MALIGNANT SYNDROME IN CHILDREN

2006 ◽  
Vol 37 (S 1) ◽  
Author(s):  
JW Miller-Horn ◽  
S Kumar ◽  
T Soman ◽  
DS Khurana ◽  
A Legido ◽  
...  
Keyword(s):  
Neuroleptic Malignant Syndrome
Sign in / Sign up

Export Citation Format

Share Document